Cat. No.: HY-13271A

Tubastatin A

Name: Tubastatin A
Brand: MedChemExpress
SKU: HY-13271A
Price: 40.00 USD
Availability: InStock
Rating: 5 (42 reviews)

42 Cited Publications

Avis client

Based on 42 publication(s) in Google Scholar

Tubastatin A is a potent and selective HDAC6 inhibitor with an IC₅₀ of 15 nM in a cell-free assay, and is selective (1000-fold more) against all other isozymes except HDAC8 (57-fold more). Tubastatin A also inhibits HDAC10 and metallo-β-lactamase domain-containing protein 2 (MBLAC2).

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.07%
CAS No.: 1252003-15-8
Formule: C₂₀H₂₁N₃O₂
Masse moléculaire:335.40

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Tubastatin A Chemical Structure

CAS No.: 1252003-15-8

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (42)
Solvant et solubilité
- In Vitro
- In Vivo
Protocole
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target^[1]

HDAC6

15 nM (IC₅₀)

HDAC8

854 nM (IC₅₀)

HDAC1

16400 nM (IC₅₀)

Voir tous les produits spécifiques à Isoform Beta-lactamase :

Voir tous les produits spécifiques à Isoform HDAC :

Cellular Effect

Cell Line	Type	Value	Description	References
697	IC₅₀	2006 nM Compound: Tubastatin A	Cytotoxicity against human 697 cells after 48 hrs by CellTiter 96 aqueous one solution assay Cytotoxicity against human 697 cells after 48 hrs by CellTiter 96 aqueous one solution assay	[PMID: 31710483]
A549	GI₅₀	>5 μM Compound: 3	Antiproliferative activity against human A549 cells after 48 hrs by SRB assay Antiproliferative activity against human A549 cells after 48 hrs by SRB assay	[PMID: 28038324]
A549	GI₅₀	>5 μM Compound: Tubastatin A	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by Sulforhodamine B assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by Sulforhodamine B assay	[PMID: 31924504]
B16	GI₅₀	40.5 μM Compound: Tubastatin A	Growth inhibition of mouse B16 cells incubated for 48 hrs by MTT assay Growth inhibition of mouse B16 cells incubated for 48 hrs by MTT assay	[PMID: 23009203]
CAL-27	IC₅₀	4.6 μM Compound: Tubastatin A	Antiproliferative activity against human CAL27 cells measured after 72 hrs by MTT assay Antiproliferative activity against human CAL27 cells measured after 72 hrs by MTT assay	[PMID: 28581289]
HCT-116	IC₅₀	2 μM Compound: Tubastatin A	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 27541357]
HCT-116	GI₅₀	>5 μM Compound: 3	Antiproliferative activity against human HCT116 cells after 48 hrs by SRB assay Antiproliferative activity against human HCT116 cells after 48 hrs by SRB assay	[PMID: 28038324]
HCT-116	IC₅₀	2 μM Compound: Tubastatin A	Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay Antiproliferative activity against human HCT116 cells after 72 hrs by MTT assay	[PMID: 28953386]
HCT-116	IC₅₀	2 μM Compound: Tubastatin A	Antiproliferative activity against human HCT116 cells Antiproliferative activity against human HCT116 cells	[PMID: 29945795]
HCT-116	GI₅₀	>5 μM Compound: Tubastatin A	Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 48 hrs by Sulforhodamine B assay Antiproliferative activity against human HCT116 cells assessed as reduction in cell viability incubated for 48 hrs by Sulforhodamine B assay	[PMID: 31924504]
HEK293	IC₅₀	>50 μM Compound: Tubastatin A	Cytotoxicity against HEK293 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against HEK293 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37875056]
HEL	IC₅₀	2.54 μM Compound: 27	Antiproliferative activity against human HEL cells after 48 hrs in presence of JAK2 inhibitor CYT-387 by CCK-8 assay Antiproliferative activity against human HEL cells after 48 hrs in presence of JAK2 inhibitor CYT-387 by CCK-8 assay	[PMID: 29940115]
HEL	IC₅₀	3.75 μM Compound: 27	Antiproliferative activity against human HEL cells after 48 hrs by CCK-8 assay Antiproliferative activity against human HEL cells after 48 hrs by CCK-8 assay	[PMID: 29940115]
HEL	IC₅₀	8.09 μM Compound: Tubastatin A	Antiproliferative activity against human HEL cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Antiproliferative activity against human HEL cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 33992929]
HEL 92.1.7	IC₅₀	>2 μM Compound: Tubastatin A	Antiproliferative activity against HEL 92.1.7 cells harboring JAK2 V617F mutant after 36 hrs by PrestoBlue dye based assay Antiproliferative activity against HEL 92.1.7 cells harboring JAK2 V617F mutant after 36 hrs by PrestoBlue dye based assay	[PMID: 27541357]
HEL 92.1.7	IC₅₀	>4 μM Compound: Tubastatin A	Antiproliferative activity against human HEL 92.1.7 cells after 36 hrs by PrestoBlue dye based assay Antiproliferative activity against human HEL 92.1.7 cells after 36 hrs by PrestoBlue dye based assay	[PMID: 28953386]
HeLa	IC₅₀	2.5 μM Compound: Tubastatin A	Inhibition of HDAC6 in human HeLa cells assessed as reduction in K40 hyperacetylation of alpha-tubulin incubated for 6 hrs by immunofluorescence assay Inhibition of HDAC6 in human HeLa cells assessed as reduction in K40 hyperacetylation of alpha-tubulin incubated for 6 hrs by immunofluorescence assay	[PMID: 25454270]
HeLa S3	IC₅₀	0.031 μM Compound: Tubastatin	Inhibition of HDAC6 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA Inhibition of HDAC6 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA	[PMID: 28337317]
HeLa S3	IC₅₀	2.7 μM Compound: Tubastatin	Inhibition of HDAC1 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA Inhibition of HDAC1 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA	[PMID: 28337317]
HeLa S3	IC₅₀	2.9 μM Compound: Tubastatin	Inhibition of HDAC3 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA Inhibition of HDAC3 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA	[PMID: 28337317]
HeLa S3	IC₅₀	3.9 μM Compound: Tubastatin	Inhibition of HDAC2 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA Inhibition of HDAC2 in human HeLaS3 cells preincubated for 15 mins followed by HDAC-Glo substrate addition measured after 30 to 45 mins by ELISA	[PMID: 28337317]
HL-60	IC₅₀	>4 μM Compound: Tubastatin A	Antiproliferative activity against human HL60 cells Antiproliferative activity against human HL60 cells	[PMID: 27541357]
HL-60	IC₅₀	>4 μM Compound: Tubastatin A	Antiproliferative activity against human HL60 cells Antiproliferative activity against human HL60 cells	[PMID: 28953386]
HL-60	IC₅₀	2.54 μM Compound: 27	Antiproliferative activity against human HL60 cells after 48 hrs in presence of JAK2 inhibitor CYT-387 by CCK-8 assay Antiproliferative activity against human HL60 cells after 48 hrs in presence of JAK2 inhibitor CYT-387 by CCK-8 assay	[PMID: 29940115]
HL-60	IC₅₀	3.75 μM Compound: 27	Antiproliferative activity against human HL60 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human HL60 cells after 48 hrs by CCK-8 assay	[PMID: 29940115]
HL-60	IC₅₀	4.09 μM Compound: Tubastatin A	Antiproliferative activity against human HL-60 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Antiproliferative activity against human HL-60 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 33992929]
Huh-7	CC₅₀	11 μM Compound: Tubastatin A	Cytotoxicity against human HuH7 cells assessed as reduction in cell viability incubated for 3 days by MTT assay Cytotoxicity against human HuH7 cells assessed as reduction in cell viability incubated for 3 days by MTT assay	[PMID: 31201063]
HUVEC	IC₅₀	69.23 μM Compound: Tubastatin A	Cytotoxicity against human HUVEC cells assessed as decrease in cell viability after 48 hrs by MTT assay Cytotoxicity against human HUVEC cells assessed as decrease in cell viability after 48 hrs by MTT assay	[PMID: 33992929]
HUVEC	IC₅₀	29.17 μM Compound: TubA	Cytotoxicity against HUVEC cells incubated for 72 hrs by CCK-8 assay Cytotoxicity against HUVEC cells incubated for 72 hrs by CCK-8 assay	[PMID: 36182802]
Jurkat	IC₅₀	3.38 μM Compound: Tubastatin A	Cytotoxicity against human Jurkat cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against human Jurkat cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 24304348]
Jurkat	IC₅₀	>4 μM Compound: Tubastatin A	Antiproliferative activity against human Jurkat cells Antiproliferative activity against human Jurkat cells	[PMID: 27541357]
Jurkat	IC₅₀	>4 μM Compound: Tubastatin A	Antiproliferative activity against human Jurkat cells Antiproliferative activity against human Jurkat cells	[PMID: 28953386]
Jurkat	IC₅₀	14.58 μM Compound: Tubastatin A	Antiproliferative activity against human Jurkat cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Antiproliferative activity against human Jurkat cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 33992929]
K562	IC₅₀	2.54 μM Compound: 27	Antiproliferative activity against human K562 cells after 48 hrs in presence of JAK2 inhibitor CYT-387 by CCK-8 assay Antiproliferative activity against human K562 cells after 48 hrs in presence of JAK2 inhibitor CYT-387 by CCK-8 assay	[PMID: 29940115]
K562	IC₅₀	3.75 μM Compound: 27	Antiproliferative activity against human K562 cells after 48 hrs by CCK-8 assay Antiproliferative activity against human K562 cells after 48 hrs by CCK-8 assay	[PMID: 29940115]
K562	IC₅₀	2.07 μM Compound: Tubastatin A	Cytotoxicity against human K562 cells incubated for 72 hrs by Sulphorhodamine assay Cytotoxicity against human K562 cells incubated for 72 hrs by Sulphorhodamine assay	[PMID: 37146520]
KB	IC₅₀	14.81 μM Compound: Tubastatin A	Cytotoxicity against human KB cells after 72 hrs by MTS assay Cytotoxicity against human KB cells after 72 hrs by MTS assay	[PMID: 25899338]
KG-1	IC₅₀	8.82 μM Compound: Tubastatin A	Antiproliferative activity against human KG-1 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Antiproliferative activity against human KG-1 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 33992929]
L02	IC₅₀	>50 μM Compound: Tubastatin A	Cytotoxicity against human L02 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Cytotoxicity against human L02 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37875056]
LNCaP	IC₅₀	10.88 μM Compound: Tubastatin A	Cytotoxicity against androgen-dependent human LNCAP cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against androgen-dependent human LNCAP cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 24304348]
LNCaP	GI₅₀	5 μM Compound: TUB A	Antiproliferative activity against human LNCaP cells assessed as growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human LNCaP cells assessed as growth inhibition incubated for 72 hrs by MTT assay	[PMID: 37633202]
MCF7	IC₅₀	3.7 μM Compound: Tubastatin A	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 27541357]
MCF7	IC₅₀	3.7 μM Compound: Tubastatin A	Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay	[PMID: 28953386]
MCF7	IC₅₀	3.7 μM Compound: Tubastatin A	Antiproliferative activity against human MCF7 cells Antiproliferative activity against human MCF7 cells	[PMID: 29945795]
MDA-MB-231	IC₅₀	10.4 μM Compound: Tubastatin A	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 27541357]
MDA-MB-231	IC₅₀	10.4 μM Compound: Tubastatin A	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by MTT assay	[PMID: 28953386]
MDA-MB-231	IC₅₀	10.4 μM Compound: Tubastatin A	Antiproliferative activity against human MDA-MB-231 cells Antiproliferative activity against human MDA-MB-231 cells	[PMID: 29945795]
MM1.S	IC₅₀	9.45 μM Compound: Tubastatin A	Antiproliferative activity against human MM1.S cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human MM1.S cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37875056]
N2a	EC₅₀	145 nM Compound: TubA	Inhibition of HDAC6 in mouse N2A cells assessed as increase in alpha tubulin acetylation Inhibition of HDAC6 in mouse N2A cells assessed as increase in alpha tubulin acetylation	[PMID: 32435374]
N2a	IC₅₀	4.4 nM Compound: TubA	Inhibition of HDAC6 in mouse N2A cells Inhibition of HDAC6 in mouse N2A cells	[PMID: 32435374]
N2a	IC₅₀	8100 nM Compound: TubA	Inhibition of HDAC1 in mouse N2A cells Inhibition of HDAC1 in mouse N2A cells	[PMID: 32435374]
NCI-H929	IC₅₀	15.42 μM Compound: Tubastatin A	Antiproliferative activity against human NCI-H929 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay Antiproliferative activity against human NCI-H929 cells assessed as inhibition of cell proliferation after 48 hrs by MTT assay	[PMID: 33992929]
PC-3	IC₅₀	8.6 μM Compound: Tubastatin A	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 27541357]
PC-3	GI₅₀	>5 μM Compound: 3	Antiproliferative activity against human PC3 cells after 48 hrs by SRB assay Antiproliferative activity against human PC3 cells after 48 hrs by SRB assay	[PMID: 28038324]
PC-3	IC₅₀	8.6 μM Compound: Tubastatin A	Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay Antiproliferative activity against human PC3 cells after 72 hrs by MTT assay	[PMID: 28953386]
PC-3	IC₅₀	8.6 μM Compound: Tubastatin A	Antiproliferative activity against human PC3 cells Antiproliferative activity against human PC3 cells	[PMID: 29945795]
RPMI-8226	IC₅₀	9.45 μM Compound: Tubastatin A	Antiproliferative activity against human RPMI-8226 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human RPMI-8226 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37875056]
RWPE-1	GI₅₀	20.2 μM Compound: TUB A	Antiproliferative activity against human RWPE-1 cells assessed as growth inhibition incubated for 72 hrs by MTT assay Antiproliferative activity against human RWPE-1 cells assessed as growth inhibition incubated for 72 hrs by MTT assay	[PMID: 37633202]
Sf21	IC₅₀	>10000 nM Compound: Tubastatin A	Inhibition of recombinant human C-terminal FLAG/His-tagged HDAC1 (1 to 482 residues) expressed in Sf21 insect cells by using RHK-K(Ac)-AMC as substrate measured after 60 mins by fluorescence assay Inhibition of recombinant human C-terminal FLAG/His-tagged HDAC1 (1 to 482 residues) expressed in Sf21 insect cells by using RHK-K(Ac)-AMC as substrate measured after 60 mins by fluorescence assay	[PMID: 31924504]
Sf9	IC₅₀	15 nM Compound: Tubastatin A	Inhibition of human recombinant HDAC6 expressed in Sf9 cells incubated for 2 hrs using RHKK-Ac fluorogenic substrate Inhibition of human recombinant HDAC6 expressed in Sf9 cells incubated for 2 hrs using RHKK-Ac fluorogenic substrate	[PMID: 23009203]
Sf9	IC₅₀	16400 nM Compound: Tubastatin A	Inhibition of human recombinant HDAC1 expressed in Sf9 cells incubated for 2 hrs using RHKK-Ac fluorogenic substrate Inhibition of human recombinant HDAC1 expressed in Sf9 cells incubated for 2 hrs using RHKK-Ac fluorogenic substrate	[PMID: 23009203]
Sf9	IC₅₀	>30000 nM Compound: tubustatin A	Inhibition of human recombinant HDAC11 expressed in baculovirus/sf9 cells using RHKKAc as substrate Inhibition of human recombinant HDAC11 expressed in baculovirus/sf9 cells using RHKKAc as substrate	[PMID: 23905680]
Sf9	IC₅₀	>30000 nM Compound: tubustatin A	Inhibition of human recombinant HDAC2 expressed in baculovirus/sf9 cells using RHKKAc as substrate Inhibition of human recombinant HDAC2 expressed in baculovirus/sf9 cells using RHKKAc as substrate	[PMID: 23905680]
Sf9	IC₅₀	15 nM Compound: tubustatin A	Inhibition of human recombinant HDAC6 expressed in baculovirus/sf9 cells using RHKKAc as substrate Inhibition of human recombinant HDAC6 expressed in baculovirus/sf9 cells using RHKKAc as substrate	[PMID: 23905680]
Sf9	IC₅₀	16400 nM Compound: tubustatin A	Inhibition of human recombinant HDAC1 expressed in baculovirus/sf9 cells using RHKKAc as substrate Inhibition of human recombinant HDAC1 expressed in baculovirus/sf9 cells using RHKKAc as substrate	[PMID: 23905680]
Sf9	IC₅₀	854 nM Compound: tubustatin A	Inhibition of human recombinant HDAC8 expressed in baculovirus/sf9 cells using RHKAcKAc as substrate Inhibition of human recombinant HDAC8 expressed in baculovirus/sf9 cells using RHKAcKAc as substrate	[PMID: 23905680]
Sf9	IC₅₀	>30000 nM Compound: tubustatin A	Inhibition of human recombinant HDAC10 expressed in baculovirus/sf9 cells using RHKKAc as substrate Inhibition of human recombinant HDAC10 expressed in baculovirus/sf9 cells using RHKKAc as substrate	[PMID: 23905680]
Sf9	IC₅₀	0.0035 μM Compound: Tubastatin A	Inhibition of full length human recombinant N-terminal GST-tagged HDAC6 (1 to 1215 residues) expressed in sf9 cells preincubated with enzyme followed by fluorogenic Arg-His-Lys-Lys(Ac)-AMC substrate addition measured after 2 hrs by fluorescence assay Inhibition of full length human recombinant N-terminal GST-tagged HDAC6 (1 to 1215 residues) expressed in sf9 cells preincubated with enzyme followed by fluorogenic Arg-His-Lys-Lys(Ac)-AMC substrate addition measured after 2 hrs by fluorescence assay	[PMID: 27541357]
Sf9	IC₅₀	11 nM Compound: Tubastatin A	Inhibition of full length human recombinant N-terminal GST-tagged HDAC6 (1 to 1215 residues) expressed in sf9 cells using RHK-K(Ac)-AMC as substrate by fluorescence assay Inhibition of full length human recombinant N-terminal GST-tagged HDAC6 (1 to 1215 residues) expressed in sf9 cells using RHK-K(Ac)-AMC as substrate by fluorescence assay	[PMID: 27541357]
Sf9	IC₅₀	>2000 nM Compound: Tubastatin A	Inhibition of human recombinant GST-tagged HDAC1 expressed in baculovirus infected Sf9 insect cells using MOCPAC as substrate after 4 hrs by UHPLC-ESI-MS/MS analysis Inhibition of human recombinant GST-tagged HDAC1 expressed in baculovirus infected Sf9 insect cells using MOCPAC as substrate after 4 hrs by UHPLC-ESI-MS/MS analysis	[PMID: 27650925]
Sf9	IC₅₀	14 nM Compound: Tubastatin A	Inhibition of recombinant full length N-terminal GST-tagged human HDAC6 expressed in baculovirus infected Sf9 cells using Z-Lys(Ac)-AMC as substrate incubated for 90 mins followed by trypsin addition and measured after 30 mins by fluorescence based assay Inhibition of recombinant full length N-terminal GST-tagged human HDAC6 expressed in baculovirus infected Sf9 cells using Z-Lys(Ac)-AMC as substrate incubated for 90 mins followed by trypsin addition and measured after 30 mins by fluorescence based assay	[PMID: 31391882]
Sf9	IC₅₀	2490 nM Compound: Tubastatin A	Inhibition of recombinant full length C-terminal FLAG/His-tagged human HDAC1 expressed in baculovirus infected Sf9 cells using Z-Lys(Ac)-AMC as substrate incubated for 90 mins followed by trypsin addition and measured after 30 mins by fluorescence based a Inhibition of recombinant full length C-terminal FLAG/His-tagged human HDAC1 expressed in baculovirus infected Sf9 cells using Z-Lys(Ac)-AMC as substrate incubated for 90 mins followed by trypsin addition and measured after 30 mins by fluorescence based a	[PMID: 31391882]
Sf9	IC₅₀	21 nM Compound: Tubastatin A	Inhibition of recombinant full length human N-terminal GST-tagged HDAC6 expressed in baculovirus infected sf9 insect cells pretreated with compound followed by Fluor de Lys deacetylase substrate addition by fluorescence method Inhibition of recombinant full length human N-terminal GST-tagged HDAC6 expressed in baculovirus infected sf9 insect cells pretreated with compound followed by Fluor de Lys deacetylase substrate addition by fluorescence method	[PMID: 31710483]
SH-SY5Y	IC₅₀	1109.7 nM Compound: Tubastatin A	Inhibition of HDAC1 in human SHSY5Y cells using MOCPAC as substrate after 8 hrs by UHPLC-ESI-MS/MS analysis Inhibition of HDAC1 in human SHSY5Y cells using MOCPAC as substrate after 8 hrs by UHPLC-ESI-MS/MS analysis	[PMID: 27650925]
SH-SY5Y	IC₅₀	122.1 nM Compound: Tubastatin A	Inhibition of HDAC in human SHSY5Y cells using MAL as substrate after 8 hrs by UHPLC-ESI-MS/MS analysis Inhibition of HDAC in human SHSY5Y cells using MAL as substrate after 8 hrs by UHPLC-ESI-MS/MS analysis	[PMID: 27650925]
SH-SY5Y	IC₅₀	94.3 nM Compound: Tubastatin A	Inhibition of HDAC6 in human SHSY5Y cells using BATCP as substrate after 8 hrs by UHPLC-ESI-MS/MS analysis Inhibition of HDAC6 in human SHSY5Y cells using BATCP as substrate after 8 hrs by UHPLC-ESI-MS/MS analysis	[PMID: 27650925]
SH-SY5Y	IC₅₀	3.15 μM Compound: Tubastatin A	Cytotoxicity against human SH-SY5Y cells assessed as cell viability measured after 36 hrs by CCK8 assay Cytotoxicity against human SH-SY5Y cells assessed as cell viability measured after 36 hrs by CCK8 assay	[PMID: 36645952]
THP-1	IC₅₀	>10 μg/mL Compound: Tubastatin A	Cytotoxicity against human THP1 cells after 48 hrs by Alamar blue assay Cytotoxicity against human THP1 cells after 48 hrs by Alamar blue assay	[PMID: 25240614]
THP-1	IC₅₀	1.9 μg/mL Compound: Tubastatin A	Antileishmanial activity against amastigote stage of Leishmania donovani infected in human THP1 cells after 48 hrs by Alamar blue assay Antileishmanial activity against amastigote stage of Leishmania donovani infected in human THP1 cells after 48 hrs by Alamar blue assay	[PMID: 25240614]
U-266	IC₅₀	9.45 μM Compound: Tubastatin A	Antiproliferative activity against human U-266 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay Antiproliferative activity against human U-266 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay	[PMID: 37875056]
U-937	EC₅₀	83 μM Compound: Tubastatin	Cytotoxicity against human U937 cells assessed as decrease in cell viability after 44 hrs by MTT assay Cytotoxicity against human U937 cells assessed as decrease in cell viability after 44 hrs by MTT assay	[PMID: 29150330]
Vero	IC₅₀	>20 μM Compound: Tubastatin A	Cytotoxicity against African green monkey Vero cells assessed as growth inhibition after 72 hrs by MTS assay Cytotoxicity against African green monkey Vero cells assessed as growth inhibition after 72 hrs by MTS assay	[PMID: 24304348]

In Vitro

Tubastatin A is substantially selective for all 11 HDAC isoforms and maintains over 1000-fold selectivity against all isoforms excluding HDAC8, where it has approximately 57-fold selectivity. In homocysteic acid (HCA) induced neurodegeneration assays, Tubastatin A displays dose-dependent protection against HCA-induced neuronal cell death starting at 5 μM with near complete protection at 10 μM^[1]. At 100 ng/mL Tubastatin A increases Foxp³⁺ T-regulatory cells (Tregs) suppression of T cell proliferation in vitro^[2]. Tubastatin A treatment in CC12 cells would lead to myotube formation impairment when alpha-tubulin is hyperacetylated early in the myogenic process; however, myotube elongation occurs when alpha-tubulin is hyeperacetylated in myotubes^[3]. A recent study indicates that Tubastatin A treatment increases cell elasticity as revealed by atomic force microscopy (AFM) tests without exerting drastic changes to the actin microfilament or microtubule networks in mouse ovarian cancer cell lines, MOSE-E and MOSE-L^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Daily treatment of Tubastatin A at 0.5 mg/kg inhibits HDAC6 to promote Tregs suppressive activity in mouse models of inflammation and autoimmunity, including multiple forms of experimental colitis and fully major histocompatibility complex (MHC)-incompatible cardiac allograft rejection^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 1252003-15-8
Appearance Solid
Masse moléculaire 335.40
Formule C₂₀H₂₁N₃O₂
Color Off-white to light yellow
SMILES

O=C(NO)C1=CC=C(CN2C3=C(CN(C)CC3)C4=C2C=CC=C4)C=C1
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (42)

All In Vivo Efficacy StudyCell Imaging/StainingWBIFRT-PCR

Sort by:

Journal Impact Factor

Cell Host Microbe

Enterococcus faecalis-derived lactic acid suppresses macrophage activation to facilitate persistent and polymicrobial wound infections. [Abstract]

2026 Feb 11;34(2):245-262.e8. PMID: 41605216
Nat Commun

The focal adhesion kinases regulate leptin action and the weight reducing effect of HDAC6 inhibition. [Abstract]

2026 Feb 5;17(1):1212. PMID: 41644943
Acta Pharm Sin B

Development of a potential PET probe for HDAC6 imaging in Alzheimer's disease. [Abstract]

2022 Oct;12(10):3891-3904. PMID: 36213537

Tubastatin A purchased from MedChemExpress. Usage Cited in: Acta Pharm Sin B. 2022 Oct;12(10):3891-3904. [Abstract]

The baseline and blocking time-activity curves of PB118 in the mice whole brain. Compared with baseline mice, remarkably reduced radioactivity was observed in the brain of mice pretreated with Tubastatin A (3.0 mg/kg; 5 min before RI).
J Biomed Sci

Targeting enolase 1 reverses bortezomib resistance in multiple myeloma through YWHAZ/Parkin axis. [Abstract]

2025 Jan 20;32(1):9. PMID: 39828712
Adv Sci (Weinh)

The Probiotic Parabacteroides johnsonii Ameliorates Metabolic Disorders Through Promoting BCAAs to BSCFAs Conversion. [Abstract]

2025 Aug 7:e02624. PMID: 40772426
Cell Death Differ

Histone deacetylase 6 deacetylates and ubiquitinates ATG3 to regulate autophagy. [Abstract]

2025 Jul 30. PMID: 40739328
Cell Death Dis

HDAC6-dependent deacetylation of TAK1 enhances sIL-6R release to promote macrophage M2 polarization in colon cancer. [Abstract]

2022 Oct 21;13(10):888. PMID: 36270986

Tubastatin A purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2022 Oct 21;13(10):888. [Abstract]

Construction of HCT116 cell line with stable HDAC6 knockdown. Tubastatin A HCl is HDAC6 selective inhibitor.
NPJ Precis Oncol

Connectivity mapping-based identification of pharmacological inhibitor targeting HDAC6 in aggressive pancreatic ductal adenocarcinoma. [Abstract]

2024 Mar 7;8(1):66. PMID: 38454151
Antioxidants (Basel)

Sp1 S-Sulfhydration Induced by Hydrogen Sulfide Inhibits Inflammation via HDAC6/MyD88/NF-κB Signaling Pathway in Adjuvant-Induced Arthritis. [Abstract]

2022 Apr 7;11(4):732. PMID: 35453416
Antioxidants (Basel)

Inhibition of HDAC6 Attenuates Diabetes-Induced Retinal Redox Imbalance and Microangiopathy. [Abstract]

2020 Jul 9;9(7):599. PMID: 32660051
Free Radic Biol Med

HDAC inhibition protects RPE cells from oxidative stress via enhanced mitochondrial fusion, cytoskeletal repair, and Nrf-2 activation. [Abstract]

2025 Aug 13:240:59-70. PMID: 40816649
Clin Transl Med

Pathogenic variants of TUBB8 cause oocyte spindle defects by disrupting with EB1/CAKP5 interactions and potential treatment targeting microtubule acetylation through HDAC6 inhibition. [Abstract]

2025 Jan;15(1):e70193. PMID: 39834092

Tubastatin A purchased from MedChemExpress. Usage Cited in: Clin Transl Med. 2025 Jan;15(1):e70193. [Abstract]

The inhibition of HDAC6 restored the spindle assembly caused by TUBB8 missense variants. Representative confocal images showed spindle morphology in groups of WT, D417N (DMSO), D417N + tubacin (2 μM), and D417N + Tubastatin A (10 μM; DMSO).
Neurotherapeutics

Axonal Transport Defect in Gigaxonin Deficiency Rescued by Tubastatin A. [Abstract]

2023 Jul;20(4):1215-1228. PMID: 37268847

Tubastatin A purchased from MedChemExpress. Usage Cited in: Neurotherapeutics. 2023 Jul;20(4):1215-1228. [Abstract]

Tubastatin A (TubA) (1 μM; overnight) treatment restores mitochondrial transport in cultured Gan^−/− DRG neurons. Graph represents the significant increase in the total movement of mitochondria in Tubastatin A (TubA)-treated Gan^−/− DRG neurons.

Tubastatin A purchased from MedChemExpress. Usage Cited in: Neurotherapeutics. 2023 Jul;20(4):1215-1228. [Abstract]

Tubastatin A (TubA) (1 μM; overnight) treatment increased levels of acetylated tubulin and Prph in the sciatic nerve of Gan^−/−;TgPer mice. The figure represented the western blots for Nefl, Prph, acetyl tubulin, and α-tubulin, respectively, from the sciatic nerve of saline- and Tubastatin A (TubA)-treated mice.

Tubastatin A purchased from MedChemExpress. Usage Cited in: Neurotherapeutics. 2023 Jul;20(4):1215-1228. [Abstract]

Immunostaining of Nefl and Prph was performed on the cell body area of spinal neurons (larger than 250 μm²) from saline- and Tubastatin A (TubA)-treated mice, followed by quantification of the signal intensity. There was a significant decrease in the signal intensity for Nefl and Prph proteins in the perikaryon of spinal neurons from Gan^−/−;TgPer mice treated with Tubastatin A (TubA) when compared to saline-treated Gan^−/−;TgPer mice.
J Med Chem

Discovery of a Novel Benzimidazole Derivative Targeting Histone Deacetylase to Induce Ferroptosis and Trigger Immunogenic Cell Death. [Abstract]

2024 Sep 12;67(17):15098-15117. PMID: 39145486
J Med Chem

Development and Pharmacochemical Characterization Discover a Novel Brain-Permeable HDAC11-Selective Inhibitor with Therapeutic Potential by Regulating Neuroinflammation in Mice. [Abstract]

2023 Dec 14;66(23):16075-16090. PMID: 37972387
Atherosclerosis

Targeting HDAC6 attenuates nicotine-induced macrophage pyroptosis via NF-κB/NLRP3 pathway. [Abstract]

2021 Jan:317:1-9. PMID: 33321327
Virulence

The inhibitory and anti-inflammatory effects of TMP269 on peste des petits ruminants virus replication. [Abstract]

2025 Dec;16(1):2495838. PMID: 40275702
Mol Cancer Res

Constitutive β-Catenin Overexpression Represses Lncrna MIR100HG Transcription via HDAC6-Mediated Histone Modification in Colorectal Cancer. [Abstract]

2022 Jun 3;20(6):949-959. PMID: 35247921
Mol Cancer Res

NEDD9 regulates actin dynamics through cortactin deacetylation in an AURKA/HDAC6-dependent manner. [Abstract]

2014 May;12(5):681-93. PMID: 24574519
J Pathol

Histone deacetylase 6 inhibition attenuates pathological cardiac hypertrophy by promoting autophagy through MAP1LC3B ubiquitination. [Abstract]

2025 Apr 11. PMID: 40212005
BMC Biol

Microtubule polyglutamylation and acetylation drive microtubule dynamics critical for platelet formation. [Abstract]

2018 Oct 18;16(1):116. PMID: 30336771
Front Pharmacol

HDAC6 Inhibition Promotes Transcription Factor EB Activation and Is Protective in Experimental Kidney Disease. [Abstract]

2018 Feb 1:9:34. PMID: 29449811

Tubastatin A purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2018 Feb 1:9:34. [Abstract]

HDAC6 inhibition with Tubastatin A acetylates TFEB, facilitates TFEB nuclear translocation and attenuates programmed cell death in NRK-52E cells. Immunoblotting for acetylated α-tubulin in NRK-52E cells treated with Tubastatin A.
PLoS Pathog

PCV2 targets cGAS to inhibit type I interferon induction to promote other DNA virus infection. [Abstract]

2021 Sep 20;17(9):e1009940. PMID: 34543359
Am J Pathol

Inhibition of Histone Deacetylase 6 by Tubastatin A Attenuates the Progress of Osteoarthritis via Improving Mitochondrial Function. [Abstract]

2020 Dec;190(12):2376-2386. PMID: 32926854
J Neurochem

Effects of Lysine Deacetylation Inhibition Alone or in Combination With Arimoclomol on TDP-43 Proteinopathy. [Abstract]

2026 Jun;170(6):e70493. PMID: 42283221
J Dermatol Sci

TRPA1 promotes melanosome phagocytosis in keratinocytes via PAR-2/CYLD axis. [Abstract]

2022 Jun;106(3):181-188. PMID: 35637111
Biochim Biophys Acta Mol Cell Res

Shear stress stimulates integrin β1 trafficking and increases directional migration of cancer cells via promoting deacetylation of microtubules. [Abstract]

2020 May;1867(5):118676. PMID: 32044386
J Nutr

Dietary Glucose Increases Glucose Absorption and Lipid Deposition via SGLT1/2 Signaling and Acetylated ChREBP in the Intestine and Isolated Intestinal Epithelial Cells of Yellow Catfish. [Abstract]

2020 Jul 1;150(7):1790-1798. PMID: 32470978

Tubastatin A purchased from MedChemExpress. Usage Cited in: J Nutr. 2020 Jul 1;150(7):1790-1798. [Abstract]

Effects of TBSA (Tubastatin A) pretreatment on glucose-induced changes in mRNA amounts of genes in IECs of yellow catfish.
Naunyn Schmiedebergs Arch Pharmacol

Aucubin inhibits epithelial-mesenchymal transition and angiogenesis in colorectal cancer via the HDAC6/PI3K/Akt signaling pathway. [Abstract]

2026 Apr 18. PMID: 41999432
Viruses

HDAC6 Facilitates PRV and VSV Infection by Inhibiting Type I Interferon Production. [Abstract]

2025 Jan 13;17(1):90. PMID: 39861880
Int J Parasitol Drugs Drug Resist

2026 May 17;31:100649.
Hum Mol Genet

E3 ligase Smurf1 protects against misfolded SOD1 in neuronal cells by promoting its K63 ubiquitylation and aggresome formation. [Abstract]

2022 Jun 22;31(12):2035-2048. PMID: 35022748
J Mol Neurosci

Effects of the Glucocorticoid-Mediated Mitochondrial Translocation of Glucocorticoid Receptors on Oxidative Stress and Pyroptosis in BV-2 Microglia. [Abstract]

2024 Mar 13;74(1):30. PMID: 38478195
J Muscle Res Cell Motil

Tubastatin A attenuates impaired autophagic degradation and promotes myogenic program in skeletal muscle following downhill running. [Abstract]

2025 Nov 13. PMID: 41233637
SSRN

2026 May 21.
bioRxiv

2025 Nov 12.
bioRxiv

Closing the loop: Teaching single-cell foundation models to learn from perturbations. [Abstract]

2025 Jul 12:2025.07.08.663754. PMID: 40672312
bioRxiv

2025 January 31.
Aging (Albany NY)

Inhibition of HDAC6 by Tubastatin A reduces chondrocyte oxidative stress in chondrocytes and ameliorates mouse osteoarthritis by activating autophagy. [Abstract]

2021 Mar 19;13(7):9820-9837. PMID: 33744850
bioRxiv

2021 Feb 25.
Patent

US20180263995A1.
University of Toronto

2017 Nov.

Tubastatin A purchased from MedChemExpress. Usage Cited in: University of Toronto. 2017 Nov.

Tubastatin A induces a dose-dependent increase in acetylated α-tubulin levels in NRK-52E cells.

Solvant et solubilité

In Vitro:

DMSO : 12.5 mg/mL (37.27 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.9815 mL

14.9076 mL

29.8151 mL

5 mM

0.5963 mL

2.9815 mL

5.9630 mL

10 mM

0.2982 mL

1.4908 mL

2.9815 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1.25 mg/mL (3.73 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 1.25 mg/mL (3.73 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1.25 mg/mL (3.73 mM); Clear solution

This protocol yields a clear solution of ≥ 1.25 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 50% PEG300 50% Saline

Solubility: 25 mg/mL (74.54 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocole

Cell Assay^[1]

Primary cortical neuron cultures are obtained from the cerebral cortex of fetal Sprague-Dawley rats (embryonic day 17) as described previously. All experiments are initiated 24 hours after plating. Under these conditions, the cells are not susceptible to glutamate-mediated excitotoxicity. For cytotoxicity studies, cells are rinsed with warm PBS and then placed in minimum essential medium containing 5.5 g/L glucose, 10% fetal calf serum, 2 mM L-glutamine, and 100 μM cystine. Oxidative stress is induced by the addition of the glutamate analogue homocysteate (HCA; 5 mM) to the media. HCA is diluted from 100-fold concentrated solutions that are adjusted to pH 7.5. In combination with HCA, neurons are treated with Tubastatin A at the indicated concentrations. Viability is assessed after 24 hours by MTT assay.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[2]

The effects of HDAC6 targeting in dextran sodium sulfate (DSS) and adoptive transfer models of colitis are evaluated, using 10 mice per group. Freshly prepared 4% (wt/vol) DSS (MP Biomedicals) is added daily for 5 days to the pH-balanced tap water of WT B6 mice. Mice are treated daily for 7 days with tubacin or niltubacin (0.5 mg/kg of body weight/day, i.p.), and colitis is assessed by daily monitoring of body weight, stool consistency, and fecal blood. Stool consistency is scored as 0 (hard), 2 (soft), or 4 (diarrhea), and fecal blood (Hemoccult) is scored as 0 (absent), 2 (occult), or 4 (gross). To assess prevention of colitis in a T cell-dependent model, CD⁴⁺ CD45RBhi T cells (1×10⁶) isolated from WT mice using magnetic beads (>95% cell purity, flow cytometry) are injected i.p. into B6/Rag1^−/− mice plus CD⁴⁺ CD²⁵⁺ Tregs (1.25×10⁵) isolated using magnetic beads from HDAC6^−/− or WT mice (>90% Treg purity, flow cytometry) and mice are monitored biweekly for clinical evidence of colitis. To assess therapy of established T cell-dependent colitis, B6/Rag1^−/− mice are injected i.p. with CD⁴⁺ CD45RBhi cells (1×10⁶). Once colitis has developed, mice also receive CD⁴⁺ CD²⁵⁺ Tregs (5×10⁵ cells) isolated as described above from HDAC6^−/− or WT mice or treatment with HDAC6i (tubastatin A) or HSP90i (17-AAG). Mice are monitored for continued weight loss and stool consistency. At the cessation of the study, paraffin sections of colons stained with Alcian Blue or hematoxylin and eosin are graded histologically or evaluated by immunoperoxidase staining for Foxp³⁺ Treg infiltration.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (285 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Kyle V. Butler et al. Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A J. Am. Chem. Soc., 2010, 132 (31), pp 10842-10846 [Content Brief]

[2]. Kozyreva VK, et al. NEDD9 regulates actin dynamics through cortactin deacetylation in an AURKA/HDAC6-dependent manner. Mol Cancer Res. 2014 May;12(5):681-93. [Content Brief]

[3]. de Zoeten EF, et al. Histone deacetylase 6 and heat shock protein 90 control the functions of Foxp3(+) T-regulatory cells. Mol Cell Biol. 2011 May;31(10):2066-78. [Content Brief]

[4]. Brijmohan, Angela, et al. Role of HDAC6 in Transcription Factor EB Mediated Clearance of Misfolded Proteins in Chronic Kidney Disease. University of Toronto.Nov-2017.

[5]. Di Fulvio S, et al. Dysferlin interacts with histone deacetylase 6 and increases alpha-tubulin acetylation. PLoS One. 2011;6(12):e28563 [Content Brief]

[6]. Ketene AN, et al. Actin filaments play a primary role for structural integrity and viscoelastic response in cells. Integr Biol (Camb). 2012 May;4(5):540-9. [Content Brief]

[7]. Lechner S, Malgapo MIP, Grätz C, et al. Target deconvolution of HDAC pharmacopoeia reveals MBLAC2 as common off-target [published online ahead of print, 2022 Apr 28]. Nat Chem Biol. 2022;10.1038/s41589-022-01015-5. [Content Brief]

[8]. Géraldy M, Morgen M, Sehr P, et al. Selective Inhibition of Histone Deacetylase 10: Hydrogen Bonding to the Gatekeeper Residue is Implicated. J Med Chem. 2019;62(9):4426-4443. [Content Brief]

[9]. Severin Lechner, et al. Target deconvolution of HDAC pharmacopoeia reveals MBLAC2 as common off-target. Nat Chem Biol. 2022 Apr 28. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.9815 mL	14.9076 mL	29.8151 mL	74.5379 mL
	5 mM	0.5963 mL	2.9815 mL	5.9630 mL	14.9076 mL
	10 mM	0.2982 mL	1.4908 mL	2.9815 mL	7.4538 mL
	15 mM	0.1988 mL	0.9938 mL	1.9877 mL	4.9692 mL
	20 mM	0.1491 mL	0.7454 mL	1.4908 mL	3.7269 mL
	25 mM	0.1193 mL	0.5963 mL	1.1926 mL	2.9815 mL
	30 mM	0.0994 mL	0.4969 mL	0.9938 mL	2.4846 mL

Bioz

Keywords

Tubastatin A

42 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Tubastatin A

Entinostat

Tubacin

Ricolinostat

PCI-34051

Trichostatin A

Vorinostat

RGFP966

Mocetinostat

Romidepsin

Santacruzamate A

Panobinostat

LMK-235

Publications Citing Use of MedChemExpress (MCE) Tubastatin A

Voir tous les produits spécifiques à Isoform Beta-lactamase

Voir tous les produits spécifiques à Isoform HDAC

Activité biologique

Chemical Information

Publications (42)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Bioz

Tubastatin A

Entinostat

Tubacin

Ricolinostat

PCI-34051

Trichostatin A

Vorinostat

RGFP966

Mocetinostat

Romidepsin

Santacruzamate A

Panobinostat

LMK-235

Publications Citing Use of MedChemExpress (MCE) Tubastatin A

Voir tous les produits spécifiques à Isoform Beta-lactamase

Voir tous les produits spécifiques à Isoform HDAC

Activité biologique

Chemical Information

Publications (42)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Tubastatin A Related Classifications

HY-13271A Related Classifications

Bioz